Press release Ecully, 6 September 2021 – 8:30 am
2021 Half Year Results postponed
Spineway, specialized in innovative implants for the treatment of severe disorders of the spinal column (spine), informs 2021 half year results are delayed due to the acquisition of Distimp, event that was not foreseen at the time the news agenda was published.
Originally planned for September the 6th after stock exchange closing, half year results will finally be communicated on September the 13th after stock exchange closing.
Upcoming: 13 September 2021 – 2021 Half year results
SPINEWAY IS ELIGIBLE FOR THE PEA-PME (EQUITY SAVINGS PLANS FOR SMES)
Find out all about Spineway at www.spineway.com
This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.
Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.
Spineway has an international network of over 50 independent distributors and 90% of its revenue comes from exports.
Spineway, which is eligible for investment through FCPIs (French unit trusts specializing in innovation), has received the OSEO Excellence award since 2011 and has won the Deloitte Fast 50 award (2011). Rhône Alpes INPI Patent Innovation award (2013) – INPI Talent award (2015).
ISIN: FR0011398874 – ALSPW
Contacts :
SPINEWAY Shareholder-services line Available Tuesday through Thursday (10 a.m. – 12 p.m.) New number (no tax) 0806 70 60 60 | Eligible PEA / PME ALSPW Euronext Growth | AELIUM Finance & Communication Investor relations Solène Kennis spineway@aelium.fr |
